Page 2 - Published June News Today

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.

Browse the latest in STEM Pathways, including blog articles, Annals research, events, Academy news and more. Content Spotlight Upcoming Events Annals

Dive into the intricate world of malaria, from parasite complexities to climate change, and the latest in vaccination, vital knowledge for health care workers.

Here are the stories that captured your attention in 2023 from NPR.org and across the NPR Network.

Here are the stories that captured your attention in 2023 from NPR.org and across the NPR Network.

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.

The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

Are you looking for the best vegan fat burner supplement in 2023? This post will provide 7 brands you should try.

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.